Food Allergy Pipeline Analysis 2025 by DelveInsight | DBV Technologies, Aravax, Xencor

DelveInsight's, "Food Allergy- Pipeline Insight, 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Food Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight's analysis shows that the Food Allergy pipeline involves over 25 key companies actively developing more than 30 therapies for Food Allergy treatment.

Food Allergy Overview:

Food allergies are adverse immune responses triggered by specific foods, consistently occurring upon exposure. These reactions can affect multiple systems, including the skin, digestive, respiratory, and cardiovascular systems, and range from mild to life-threatening. Unlike food intolerances, food allergies involve the immune system and are generally more serious. They are increasingly prevalent, particularly in developed countries, affecting approximately 5-8% of children and 1-2% of adults worldwide.

Symptoms can vary from hives, swelling, breathing difficulties, and gastrointestinal issues to severe, potentially fatal reactions like anaphylaxis, which require immediate treatment. Food allergies are categorized based on immune mechanisms into three types:

*
IgE-mediated - the most common type, causing immediate allergic reactions.

*
Non-IgE-mediated - typically leading to delayed gastrointestinal symptoms.

*
Mixed-type - involving both mechanisms, producing a combination of symptoms.

The development of food allergies is influenced by genetic and environmental factors such as family history, early dietary exposure, the hygiene hypothesis, and potential vitamin D deficiency. Common allergens include milk, eggs, peanuts, tree nuts, soy, wheat, fish, and shellfish.

Diagnosis involves reviewing medical and dietary history, performing skin and blood tests, and sometimes conducting supervised food challenges. Management focuses on strict avoidance of trigger foods, educating patients on food labeling, and ensuring emergency preparedness with epinephrine auto-injectors. Although emerging therapies like oral immunotherapy show promise, they are not yet widely available. Overall, food allergies are a growing public health concern that require proper awareness, diagnosis, and management to prevent serious reactions.

Download our report @ https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Food Allergy Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Food Allergy Therapeutics Market.

Key Takeaways from the Food Allergy Pipeline Report

*
DelveInsight's Food Allergy pipeline report highlights a vibrant landscape, with over 25 active companies developing more than 30 potential therapies for Food Allergy treatment.

*
In July 2024, the FDA expanded the approval of Palforzia, a peanut allergen powder, to include children aged one to three years. Previously approved for those aged four to seventeen, Palforzia helps reduce allergic reactions, including anaphylaxis, from accidental peanut exposure.

*
Earlier in 2024, the FDA approved Xolair (omalizumab) as the first drug to lessen allergic reactions to multiple food allergens following accidental exposure. Xolair is indicated for individuals aged one year and older with IgE-mediated food allergies, providing a preventive option beyond strict dietary avoidance.

*
Effective January 1, 2023, sesame became the ninth major food allergen in the U.S. under the Food Allergy Safety, Treatment, Education, and Research (FASTER) Act. This requires clear labeling of sesame on packaged foods, enhancing safety for those with sesame allergies.

*
Key companies such as DBV Technologies, Aravax, Xencor, and others are actively developing new therapies to advance the Food Allergy treatment landscape.

*
Notable pipeline candidates under development include Viaskin Peanut, PVX-108, AIMab7195, and others.

Food Allergy Pipeline Analysis

The Food Allergy pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Food Allergy Market.

*
Categorizes Food Allergy therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Food Allergy drugs under development based on:

*
Stage of development

*
Food Allergy Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Food Allergy Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Food Allergy Licensing agreements

*
Funding and investment activities supporting future Food Allergy market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Food Allergy Emerging Drugs

*
Viaskin Peanut: DBV Technologies

*
PVX-108: Aravax

*
AIMab7195: Xencor

Food Allergy Companies

Over 25 prominent companies are actively working on therapies for food allergies, with DBV Technologies having a drug candidate that has advanced to the preregistration stage, the furthest in development.

DelveInsight's report covers around 30+ products under different phases of Food Allergy clinical trials like

*
Food Allergy Late stage Therapies (Phase III)

*
Food Allergy Mid-stage Therapies (Phase II)

*
Food Allergy Early-stage Therapies (Phase I)

*
Food Allergy Pre-clinical and Food Allergy Discovery stage Therapies

*
Food Allergy Discontinued & Inactive Therapies

Food Allergy pipeline report provides the Food Allergy therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Food Allergy Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Food Allergy Therapies and Key Food Allergy Companies: Food Allergy Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Food Allergy Pipeline Therapeutic Assessment

- Food Allergy Assessment by Product Type

- Food Allergy By Stage

- Food Allergy Assessment by Route of Administration

- Food Allergy Assessment by Molecule Type

Download Food Allergy Sample report to know in detail about the Food Allergy treatment market @ Food Allergy Therapeutic Assessment [https://www.delveinsight.com/sample-request/food-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Food Allergy Current Treatment Patterns

4. Food Allergy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Food Allergy Late-Stage Products (Phase-III)

7. Food Allergy Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Food Allergy Discontinued Products

13. Food Allergy Product Profiles

14. Food Allergy Key Companies

15. Food Allergy Key Products

16. Dormant and Discontinued Products

17. Food Allergy Unmet Needs

18. Food Allergy Future Perspectives

19. Food Allergy Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Food Allergy Pipeline Reports Offerings [https://www.delveinsight.com/report-store/food-allergy-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=food-allergy-pipeline-analysis-2025-by-delveinsight-dbv-technologies-aravax-xencor]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.